A method and system for harmless treatment of medical waste, waste drugs and medicines

Abstract

The present invention relates to the technical field of hazardous waste treatment, and discloses a harmless treatment method and system for medical waste and waste drugs and medicines, which realize harmless treatment by co-burning with medical waste, including the steps of classification and identification at the factory, formulation of a compatibility scheme, pre-furnace compatibility and incineration process control. The present invention realizes harmless treatment by co-burning medical waste and waste drugs and medicines with medical waste, and utilizes the surplus capacity of a medical waste incineration plant to dispose of medical waste and waste drugs and medicines, overcomes the relatively small amount of medical waste and waste drugs and medicines, and the environmental risks brought by the decentralized storage and decentralized disposal of medical hazardous wastes, and also saves the cost of building a centralized hazardous waste disposal facility, and can effectively meet the disposal needs of medical waste, waste drugs and medicines; at the same time, combined with the corresponding compatibility scheme and pre-furnace compatibility operation, it can dynamically change with the change of the amount of medical waste generated within the service range, has good adaptability and strong processing capacity.

Description

Technical Field

[0001] The present invention relates to the technical field of hazardous waste treatment, and in particular to a method and system for harmlessly treating medical waste and waste drugs and medicines. Background Art

[0002] The potential harm caused by the generation of pharmaceutical waste has attracted increasing attention. Pharmaceutical hazardous waste mainly includes HW02 and HW03 in the national hazardous waste list. HW02 mainly includes reaction residues, waste slag, waste materials, discarded products, etc. generated by the manufacturing of chemical raw materials, chemical pharmaceuticals, veterinary drugs, biological drugs and other industries; HW03 mainly includes expired, deteriorated, unqualified, obsolete, and inferior drugs and medicines generated during production, sales and use. The content of viral microorganisms and chemical agents in these pharmaceutical wastes is relatively high, and there are spatial infectiousness, acute infectiousness and latent infectiousness.

[0003] At present, the disposal methods for medical waste include preparing organic fertilizer from antibiotic fermentation waste residue, extracting solvents, co-disposal, incineration and harmless disposal, etc. Among them, the co-incineration and harmless disposal technology takes into account versatility and broad spectrum, and can well meet the disposal requirements of medical waste with many types, complex components, relatively small quantities and large changes. Compared with HW01 medical waste, HW02 and HW03 have greater volatile matter, greater density, and less fixed carbon. At the same time, the chlorine content, sulfur content, nitrogen content, and heavy metal (Cu, Zn, As, Hg) content of medical waste are relatively higher. Randomly mixing with HW01 medical waste for incineration can easily lead to unstable combustion and substandard exhaust emissions. No related technology has been found in the prior art for incinerating medical waste HW02 and waste drugs / medicines HW03 when incinerating medical waste HW01.

[0004] The existing medical waste incinerator can refer to the patent document with publication number CN218583174U. Summary of the invention

[0005] The purpose of the present invention is to provide a method for the mixed combustion of medical waste and waste drugs and medicines that does not affect the incineration treatment capacity of medical waste, and to at least provide a beneficial option or create conditions for solving one or more technical problems existing in the prior art.

[0006] To achieve the above objectives, the present invention adopts the following technical solutions.

[0007] A harmless treatment method for pharmaceutical waste and waste drugs and medicines, which achieves harmless treatment by incinerating with medical waste, comprises the following steps: 1) classification and identification upon entry into the factory, classification and identification of the collected medical waste, pharmaceutical waste, waste drugs / medicines and compatibility analysis, placement of the waste drugs in different areas according to factors such as compatibility and physical and chemical properties, and entry into the inventory system; 2) formulation of a compatibility plan, formulation of a daily compatibility plan for the incineration disposal line based on the actual inventory, and transfer of medical waste HW01 and the medicines for incineration from the temporary storage according to the daily compatibility plan. Waste HW02 and / or waste drugs / pharmaceuticals HW03; 3) Pre-furnace matching, mixing and proportioning medical waste, pharmaceutical waste and waste drugs / pharmaceuticals according to compatibility and furnace design indicators, the furnace design indicators include lower calorific value, sulfur content, chlorine content, fluorine content, total heavy metal content, and total mercury and arsenic content; 4) Incineration process control, before the temperature in the incinerator stabilizes, only medical waste is incinerated, and when the temperature in the furnace stabilizes at above 1100℃, medical waste, pharmaceutical waste and waste drugs / pharmaceuticals are mixed and incinerated.

[0008] More preferably, the harmless treatment method for medical waste and waste drugs and medicines also includes a full tracking step, using hazardous waste management system software to collect full information on the source, transportation unit, receiving unit, quantity, hazardous components, form, warehousing date, compatibility plan, disposal method and outbound date of all waste received into the factory, and establish a database; the material situation of the disposal center is understood at any time to facilitate the optimization of the compatibility plan.

[0009] More preferably, when medical waste, pharmaceutical waste and waste drugs / medicines are mixed and burned, the temperature fluctuation is controlled by adjusting the combustion-supporting system to ensure that the high temperature section of the incinerator is stably maintained above 1100°C.

[0010] More preferably, the furnace design indicators are: the lower calorific value after matching is between 3500 and 5200 kal / kg, the sulfur content is ≤1.5%, the chlorine content is ≤2.5%, the fluorine content is ≤0.1%, the total heavy metal content is <0.5%, and the total mercury and arsenic content is ≤0.05%, all calculated by weight percentage.

[0011] More preferably, when mixing, the sum of the amounts of medical waste and waste drugs / medicines burned does not exceed 20wt% of the total amount of hazardous waste burned.

[0012] More preferably, the classification and identification mainly includes the following contents: a) physical properties, physical composition, bulk density and size; b) industrial analysis, ash content, volatile matter, moisture content and lower calorific value; c) elemental composition and harmful substance content; d) characteristic identification, corrosiveness, leaching toxicity and flammability and explosiveness.

[0013] More preferably, the compatibility analysis is based on whether a hazard will occur when mixed, and incompatible hazardous wastes are stored separately in different storage areas and equipped with isolation facilities.

[0014] More preferably, during the co-combustion, the solid materials and waste drugs and medicines in the medical waste are placed in a turnover box and transported to the automatic feeding system of the incinerator, and then put into the incinerator for incineration by relying on the automatic feeding system; the liquid materials in the medical waste are put into the waste liquid tank and sprayed into the secondary combustion chamber for incineration through the atomization system.

[0015] More preferably, the first combustion chamber of the incinerator ensures the oxygen atmosphere required for incineration by controlling the primary air volume, and the second combustion chamber carries out oxygen combustion under the condition of secondary air oxygen supplementation, and the flue gas residence time is greater than 2s; the high-temperature flue gas from the second combustion chamber enters the waste heat recovery system, and the flue gas temperature at the outlet of the waste heat recovery system is higher than 550°C, and the flue gas from the waste heat recovery system enters the dry quench cooler, and the flue gas temperature at the outlet of the dry quench cooler is lower than 200°C.

[0016] On the other hand, the present invention also provides a harmless treatment system for medical waste and waste drugs and medicines, which is used to implement the harmless treatment method for medical waste and waste drugs and medicines as described above.

[0017] The present invention adopts the above technical solution and has at least the following beneficial effects.

[0018] 1. Mix pharmaceutical waste, waste drugs and medicines with medical waste to achieve harmless treatment, and use the surplus capacity of medical waste incineration plants to dispose of pharmaceutical waste, waste drugs and medicines, so as to overcome the relatively small amount of pharmaceutical waste, waste drugs and medicines, and the environmental risks brought about by the decentralized storage and decentralized disposal of pharmaceutical hazardous wastes, and also save the cost of building new centralized hazardous waste disposal facilities, which can effectively meet the disposal needs of pharmaceutical waste, waste drugs and medicines; at the same time, combined with the corresponding matching scheme and pre-furnace matching operation, it can dynamically change with the changes in the amount of medical waste generated within the service scope, with good adaptability and strong processing capacity.

[0019] 2. After actual incineration tests, after incinerating medical waste and waste drugs and medicines using the harmless treatment method provided by the present invention, the concentration of particulate matter, SO2, mercury and its compounds, and cadmium and its compounds in the exhaust gas all meet the standard limits and do not affect the incineration treatment of medical waste. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Shown is a process flow chart for the co-combustion of pharmaceutical waste and waste drugs / medicines. DETAILED DESCRIPTION

[0021] To facilitate those skilled in the art to better understand the essence of the present invention, the specific implementation of the present invention is described in detail below with reference to the accompanying drawings.

[0022] A method for harmlessly treating medical waste HW02 and waste drugs / medicines HW03 is achieved by co-burning with medical waste HW01, and specifically comprises the following steps.

[0023] 1) Classification and identification upon entry into the factory: collect medical waste HW01, pharmaceutical waste HW02, and waste drugs / medicines HW03, classify and identify them, and analyze their compatibility. Place them in different areas and according to factors such as compatibility and physical and chemical properties, and enter them into the inventory system.

[0024] 2) Formulate a compatibility plan. Formulate a daily compatibility plan for the incineration disposal line based on the actual inventory. According to the daily compatibility plan, medical waste HW01 and mixed pharmaceutical waste HW02 and / or waste drugs / medicines HW03 for incineration are transferred from the temporary storage.

[0025] 3) Pre-furnace preparation: medical waste HW01, pharmaceutical waste HW02, and waste drugs / medicines HW03 are mixed and proportioned according to the design indicators for entering the furnace, which include lower calorific value, sulfur content, chlorine content, fluorine content, total heavy metal content, and total mercury and arsenic content.

[0026] 4) Incineration process control: before the temperature in the incinerator stabilizes, only medical waste HW01 is incinerated. When the temperature in the furnace stabilizes at above 1100°C, medical waste HW01, pharmaceutical waste HW02 and waste drugs / medicines HW03 are mixed and incinerated.

[0027] Among them, classification and identification mainly include the following contents: a) physical properties, such as physical composition, bulk density, size, etc.; b) industrial analysis, such as ash content, volatile matter, moisture, lower calorific value, etc.; c) elemental composition and harmful substance content; d) characteristic identification, such as corrosiveness, leaching toxicity, flammability and explosiveness, etc.

[0028] In compatibility analysis, compatibility is determined based on whether it will cause danger when mixed. Incompatible hazardous wastes are stored separately in different storage areas and equipped with isolation facilities. Examples of incompatible substances are shown in Table 1.

[0029] Table 1. Examples of incompatible substances

[0030] .

[0031] When formulating the compatibility plan, the sum of the blended amounts of medical waste HW02 and waste drugs / medicines HW03 shall not exceed 20wt% of the total amount of hazardous waste incinerated to ensure stable combustion and compliance with emission standards.

[0032] When mixing in front of the furnace, avoid mixing incompatible hazardous wastes together to prevent violent reactions during the incineration process. At the same time, control the content of S, halogens, and heavy metals in hazardous wastes, and appropriately reduce the proportion of components with high content in the blending. After mixing, each index should reach the design index for entering the furnace. The design index for entering the furnace is shown in Table 2.

[0033] Table 2. Incineration process requirements

[0034] .

[0035] During the incineration process, liquid waste is directly fed into the secondary combustion chamber of the vertical pyrolysis gasification furnace incineration line by a metering pump through a pipeline. During operation, the feeding of semi-solid, solid waste and auxiliary materials is adjusted according to the working conditions (such as observing the oxygen content, the negative pressure value of the furnace, carbon monoxide, etc.). When the medical waste, pharmaceutical waste and waste drugs / medicines are mixed and burned, the temperature fluctuation is also adjusted and controlled by the combustion-supporting system to ensure that the high temperature section of the incinerator is stably maintained above 1100℃. The incineration temperature of the incinerator is strictly controlled at above 1100℃, the concentration of CO in the furnace is controlled at 50±10ppm, the volume concentration of O2 is above 6%, and the smoke retention time in the furnace is controlled to be not less than 2 seconds to ensure the full decomposition of dioxins.

[0036] In addition, the present invention uses hazardous waste management system software to collect full information on the source, transportation unit, receiving unit, quantity, hazardous components, form, storage date, compatibility plan, disposal method and storage date of all wastes received into the factory, and establish a database; the material situation of the disposal center can be understood at any time to facilitate the optimization of the compatibility plan.

[0037] Reference Figure 1As shown, it is a specific process flow for achieving the mixed combustion of medical waste HW01, pharmaceutical waste HW02 and waste drugs / medicines HW03 using a vertical pyrolysis incinerator. After inspection, identification and classification upon entry, the pharmaceutical waste HW02 and waste drugs / medicines HW03 are incinerated and disposed of according to the matching plan; during blending, the solid materials in the pharmaceutical waste HW02 and waste drugs / medicines HW03 placed in the turnover box according to the matching amount are transported to the automatic feeding system and put into the incinerator for incineration by relying on the automatic feeding system; the liquid materials in the pharmaceutical waste HW02 are put into the waste liquid tank and sprayed into the second combustion chamber for incineration through the atomization system; the first combustion chamber controls the primary air volume to ensure the oxygen atmosphere required for incineration. After the waste entering the furnace is dried, it is first thermally decomposed at an ambient temperature of 600-750℃. The decomposition products mainly include residual carbon (fixed carbon), hydrogen, methane, carbon monoxide, CO2, liquid tar, oil compounds (acetic acid, acetone, complex hydrocarbons), etc.; the residual carbon and other residues are fully burned at a temperature of 1100-1300℃ (part of the pyrolysis gas also participates in the combustion), providing the required heat source for the incineration pyrolysis and oxidation conditions. The coke-like residue after burning is cooled while preheating the primary air, and is mechanically squeezed and broken into blocks less than 110mm by the grate, discharged into the water seal tank at the bottom of the furnace, and discharged through the wet slag discharge system. The mixed flue gas produced in the first combustion chamber enters the second combustion chamber, and is burned with oxygen under the condition of secondary air supplementation (diesel spray can be used to assist combustion during ignition). The temperature in the furnace is controlled above 1100℃, and the flue gas residence time is greater than 2s. The high-temperature flue gas in the second combustion chamber enters the waste heat recovery system.

[0038] The waste heat recovery system is equipped with a membrane wall waste heat boiler + a dry tube quench cooler to recover the waste heat in the flue gas and produce 1.0MPa saturated steam as a by-product. The flue gas temperature at the outlet of the waste heat boiler is set to be higher than 550℃, and the flue gas temperature at the outlet of the dry quench cooler is set to be lower than 200℃; this can shorten the residence time of the flue gas in the temperature range of 200℃~500℃ as much as possible and reduce the re-generation of dioxin-like substances.

[0039] Flue gas temperature has a great influence on dioxin removal. Dioxin is a compound with a high boiling point and low vapor pressure, so when the flue gas temperature is low, dioxin gas is more easily converted into fine particles. It can be inferred that under lower gas phase temperature conditions, bag filters can remove dioxins more effectively.

[0040] A semi-dry + dry acid removal purification process is used before the bag filter. At the same time, compressed air transports activated carbon to the pipeline in front of the filter to remove heavy metals and dioxins through adsorption during contact with the flue gas.

[0041] Bag filter has a good removal effect on dioxins and heavy metals. When the flue gas passes through the activated carbon injection device and the filter bag of the bag filter, the dioxins generated by the reaction will be adsorbed and gradually accumulated on the dust layer due to the lime powder layer attached to the filter bag and the activated carbon powder with a very large specific surface area, and the dioxins are removed from the flue gas. According to the existing engineering supervisory monitoring data of the plant area, by taking a series of pollution prevention and control measures such as activated carbon adsorption, the concentration of dioxins in the exhaust gas can be controlled at 0.1ngTEQ / m 3 Below the level (the standard limit is 0.5ngTEQ / m 3 ); ensure safe emission that meets standards. Example

[0042] In this embodiment, the analysis data of each hazardous waste is shown in Table 3, and the component analysis data are all average values ​​of multiple sample measurements.

[0043] Table 3. Composition of incinerated materials

[0044] .

[0045] In this embodiment, the compatibility components when using a vertical pyrolysis incinerator to incinerate hazardous waste are shown in Table 4.

[0046] Table 4. Composition of hazardous wastes to be incinerated in an incinerator

[0047] .

[0048] In this embodiment, the calorific value of the hazardous waste to be incinerated in the vertical pyrolysis incinerator is 4438 kcal / kg, the S content is 0.26%, the Cl content is 1.66%, the F content is 0.0016%, the total heavy metal content is 0.00003%, and the total mercury and arsenic content is 0.000001%, all of which meet the design index requirements for entering the furnace.

[0049] Comparison example.

[0050] The control example is the incineration of medical waste HW01 alone, with a processing scale of 35 t / d; the rest is consistent with the embodiment.

[0051] Performance comparison.

[0052] 1) Comparison of incinerator operation and flue gas emissions. The results are shown in Table 5.

[0053] Table 5. Comparison of incinerator operation and flue gas emissions

[0054] Blending ratio A combustion chamber temperature Second combustion chamber temperature Flue gas temperature Flue gas velocity <![CDATA[O2 (Dry)]]> Water content unit ℃ ℃ ℃ m / s % % 0 899.7 1176.7 102.4 10.2 12.4 15.3 20% 945.9 1188.9 105.8 10.4 10.6 16.1 .

[0055] As can be seen from Table 5, after the incineration of 20wt% of medical waste HW02 and waste medicine / waste pharmaceutical HW03, the furnace temperature and main steam temperature remain basically unchanged, the flue gas temperature rises slightly, but not significantly, the flue gas flow rate has no obvious difference, and the moisture content of the flue gas rises by about 1%. It can be seen that at the set 20wt% incineration ratio, the working performance of the waste incinerator will not be affected.

[0056] 2) Comparison of organized waste gas emissions before and after blending, as shown in Table 6.

[0057] Table 6. Comparison of organized waste gas emissions before and after blending

[0058] .

[0059] It can be seen from Table 6 that under the same flue gas treatment measures, after the blending and combustion of 20wt% of medical waste HW02 and waste medicine / waste drug HW03, the concentration of particulate matter, SO2, mercury and its compounds, and cadmium and its compounds in the exhaust gas all meet the standard limits, and some indicators are even better, which may be due to changes in the process after blending and combustion.

[0060] 3) The water quality of the comprehensive wastewater effluent before and after the blending was compared. The results are shown in Table 7.

[0061] Table 7. Comparison of water quality of comprehensive wastewater before and after blending

[0062] .

[0063] During the process of blending HW02 and HW03, the drugs were packaged, the wastewater from the turnover barrel cleaning was almost unaffected, and the storage point was dry without immersion. Therefore, the impact of blending on the comprehensive wastewater was very small. Table 7 also shows that the water quality of the wastewater did not change much before and after blending, and met the requirements for reused water after treatment.

[0064] 4) Comparison of water quality of alkali washing wastewater before and after blending. The results are shown in Table 8.

[0065] Table 8. Comparison of water quality of alkali washing wastewater before and after blending

[0066] .

[0067] It can be seen from Table 8 that there is no major change in the water quality in the alkali wash wastewater regulating tank before and after blending, and the overall impact on the water treatment system is small, and it can be treated according to the normal process.

[0068] It should be noted that the various technical features of the embodiments of the present invention can be arbitrarily combined. In order to make the description concise, not all possible combinations of the various technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0069] The above embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. The parts not described in the specific embodiments are all prior art or common knowledge.

[0070] It should be noted that, in the description of the present invention, the content of the present invention can be more easily understood by referring to the detailed description of the preferred implementation method of the present invention and the embodiments included. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those of ordinary skill in the art to which the present invention belongs. When there is a conflict, the definitions in this specification shall prevail.

[0071] In the present invention, the term "prepared from..." is used synonymously with "comprising". The terms "comprising", "including", "having", "containing" or any other variation thereof, as used in the present invention, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.

[0072] In the present invention, when an amount, concentration, or other value or parameter is expressed as a range, a preferred range, or a range limited by a series of upper preferred values ​​and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when a range of "1 to 5" is disclosed, the described range should be interpreted as including a range of "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5" etc. When a numerical range is described in the present invention, unless otherwise stated, the range is intended to include its end values ​​and all integers and fractions within the range.

[0073] In addition, the indefinite articles "a" and "an" before the elements or components of the present invention have no restrictions on the quantity requirements (i.e. the number of occurrences) of the elements or components. Therefore, "a" or "an" should be interpreted as including one or at least one, and the elements or components in the singular form also include the plural form, unless the number is obviously intended to be in the singular form.

Claims

1. A method for harmlessly treating medical waste and waste drugs and medicines, characterized in that: The harmless treatment is achieved by co-burning with medical waste, including the following steps: 1) Classification and identification of incoming medical waste, pharmaceutical waste, and waste drugs / medicines, and compatibility analysis of collected medical waste, pharmaceutical waste, and waste drugs / medicines. They are placed in different areas according to compatibility and physical and chemical properties, and entered into the inventory system; 2) Formulate a compatibility plan. Formulate a daily compatibility plan for the incineration disposal line based on the actual inventory. Transfer medical waste and mixed pharmaceutical waste and / or waste drugs / medicines from the temporary storage according to the daily compatibility plan; 3) Pre-furnace mixing: medical waste, pharmaceutical waste, and waste drugs / medicines are mixed and proportioned according to compatibility and furnace design indicators, including lower calorific value, sulfur content, chlorine content, fluorine content, total heavy metal content, and total mercury and arsenic content; when mixing, the sum of the mixed combustion amounts of medical waste and waste drugs / medicines shall not exceed 20wt% of the total amount of hazardous waste incinerated; 4) Incineration process control: before the temperature in the incinerator is stable, only medical waste is incinerated. When the temperature in the furnace is stable above 1100°C, medical waste, pharmaceutical waste and waste drugs / medicines are mixed and incinerated; During the mixed combustion, the solid materials and waste drugs and medicines in the medical waste are placed in the turnover box and transported to the automatic feeding system of the incinerator, and then put into the incinerator for incineration by relying on the automatic feeding system; the liquid materials in the medical waste are put into the waste liquid tank and sprayed into the secondary combustion chamber for incineration through the atomization system; The first combustion chamber of the incinerator ensures the oxygen atmosphere required for incineration by controlling the primary air volume. The second combustion chamber performs oxygen combustion under the condition of secondary air supplementation, and the flue gas residence time is greater than 2s; the high-temperature flue gas from the second combustion chamber enters the waste heat recovery system, and the flue gas temperature at the outlet of the waste heat recovery system is higher than 550℃. The flue gas from the waste heat recovery system enters the dry quench cooler, and the flue gas temperature at the outlet of the dry quench cooler is lower than 200℃; The flue gas at the outlet of the dry quench cooler enters the bag filter, and at the same time, the compressed air transports the activated carbon to the pipe in front of the filter.

2. A method for harmless treatment of medical waste and waste drugs and medicines according to claim 1, characterized in that: It also includes full tracking steps, using hazardous waste management system software to collect information on the source, transportation unit, receiving unit, quantity, hazardous components, form, storage date, compatibility plan, disposal method and storage date of all waste received into the factory, and establish a database; understand the material situation of the disposal center at any time to optimize the compatibility plan.

3. A method for harmless treatment of medical waste and waste drugs and medicines according to claim 1, characterized in that: When medical waste, pharmaceutical waste and waste drugs / medicines are mixed and burned, the combustion-supporting system is used to adjust and control temperature fluctuations to ensure that the high-temperature section of the incinerator remains stable at above 1100°C.

4. A method for harmless treatment of medical waste and waste drugs and medicines according to claim 1, characterized in that: The furnace design indicators are: the lower calorific value after matching is between 3500 and 5200 kal / kg, the sulfur content is ≤1.5%, the chlorine content is ≤2.5%, the fluorine content is ≤0.1%, the total heavy metal content is <0.5%, and the total mercury and arsenic content is ≤0.05%, all calculated by weight percentage.

5. The method for harmlessly treating medical waste and waste drugs and medicines according to claim 1, characterized in that: Classification and identification mainly include the following contents: a) Physical properties, physical composition, bulk density and size; b) Industrial analysis, ash content, volatile matter, moisture content and lower calorific value; c) Element composition and harmful substance content; d) Characteristic identification, corrosiveness, leaching toxicity and flammability and explosiveness.

6. A method for harmless treatment of medical waste and waste drugs and medicines according to claim 1, characterized in that: Compatibility analysis is based on whether mixing will create a hazard. Incompatible hazardous wastes are stored separately in different storage areas and are equipped with isolation facilities.

7. A harmless treatment system for medical waste, waste drugs and medicines, characterized in that: Used to realize the harmless treatment method of medical waste and waste drugs and medicines as described in any one of claims 1-6.

Images